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We draw on diverse data sets to compare the institutional organization of upstream lifescience research across the United States and Europe. Understanding cross-national
differences in the organization of innovative labor in the life sciences requires attention to
the structure and evolution of biomedical networks involving public research organizations
(universities, government laboratories, nonprofit research institutes, and research hospitals),
science-based biotechnology firms, and multinational pharmaceutical corporations. We use
network visualization methods and correspondence analyses to demonstrate that innova-
tive research in biomedicine has its origins in regional clusters in the United States and in
European nations. But the scientific and organizational composition of these regions varies
in consequential ways. In the United States, public research organizations and small firms
conduct R&D across multiple therapeutic areas and stages of the development process. Ties
within and across these regions link small firms and diverse public institutions, contributing
to the development of a robust national network. In contrast, the European story is one of
regional specialization with a less diverse group of public research organizations working
in a smaller number of therapeutic areas. European institutes develop local connections to
small firms working on similar scientific problems, while cross-national linkages of Euro-
pean regional clusters typically involve large pharmaceutical corporations. We show that the
roles of large and small firms differ in the United States and Europe, arguing that the greater
heterogeneity of the U.S. system is based on much closer integration of basic science and
clinical development.
(University-Industry Relations; National Innovation Systems; R&D Networks; Spatial Clustering;
Network Visualization)
1. Introduction
Universities in the United States and Europe are often
compared with respect to their divergent levels of
involvement in the private economy. The U.S. uni-
versity system, with its mix of both public and pri-
vate institutions, has long played a significant role
in conducting research that contributes to technolog-
ical development and industrial performance (Geiger
1988, Rosenberg and Nelson 1994). Historically, this
“knowledge plus” orientation, in which high-quality
public and academic research tends to be driven
by “joint goals of understanding and use” (Stokes
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1997, p. 15) was contrasted to the European scene,
where universities were believed to contribute more
to knowledge for its own sake and to the preservation
of distinctive national cultures (Ben-David 1977).
Over the past decade, the development of a number
of key science and technology-based industries—most
notably information and communication technolo-
gies, and biotechnology—has helped spark economic
growth. The United States has broad commercial lead-
ership in a number of these new areas, and com-
mentators suggest that U.S. universities and research
institutes played a significant role in this process
(Mowery and Nelson 1999, Mowery et al. 2001).
The diverse interfaces between U.S. research univer-
sities and the private sector have been widely doc-
umented (Link 1999, Mowery 1999). Patenting by
U.S. universities increased nearly sevenfold over the
period 1976–1998 (Owen-Smith 2000) and licensing
revenues from the sale of intellectual property have
grown briskly as well. The science-based start-up firm
has been the cornerstone of the commercial field of
biotechnology, with university researchers playing a
significant role as founders, consultants, and members
of scientific advisory boards.
In contrast, industry-university relations in Europe
have lagged behind, in part because of legal prohi-
bitions in some countries against faculty collabora-
tion with commercial entities and cultural predisposi-
tions against academic involvement with commerce.
Since the late 1980s, however, European attention has
shifted to technology policy and academic technology
transfer (Howells and McKinlay 1999). In a climate
of strong anxiety about European Union competitive-
ness in science-based industries, programs developed
following the Single European Act of 19871 encourage
matches between universities and firms, placing par-
ticular emphasis on quick delivery of tangible com-
mercial results (Peterson and Sharp 1998).
Strong contrasts exist between European and U.S.
research infrastructures, however. Consider, as an
illustration, differences in university organization and
1 The Single European Act provided, for the first time, a legal basis
for European R&D programs (framework programs) developed
by the European Commission to complement national programs
and funds.
governance between the United States and Germany.
The U.S. system is highly decentralized. Even public
universities rely on diverse funding sources, includ-
ing state and national governments, foundations and
corporate supporters, tuition revenues, and alumni
gifts. Private universities, especially elite ones, are
also supported by generous endowments. Financ-
ing is considerably more centralized within European
nations, and this centralization entails more hierar-
chical control. Faculty members in the United States
have much more research independence at early
career stages, and academic scientists frequently
move between universities in an effort to better their
labor market position. In France and elsewhere on the
continent, there is much less autonomy and mobility
for younger scientists (Gittelman 2000). In addition,
blurring boundaries between basic and goal-oriented
research and increased competition for research sup-
port and funding enable greater mixing of disciplines
in the United States (Galambos and Sturchio 1998,
Morange 1998). In Germany, a number of the highly
prestigious Max Planck institutes are organized hier-
archically around a single field, such as biochemistry,
genetics, or immunology. Elite research institutes in
the United States, such as Cold Spring Harbor, Salk,
or Scripps, routinely bring together faculty from mul-
tiple disciplines.
Against this background, we undertake a broad
comparison of linkages between research universities,
public research institutes and the private sector in the
field of the life sciences and analyze how differences
in the pattern of these relationships have shaped the
development of biotechnology in the United States
and Europe. The explosion of knowledge in molecu-
lar biology and genetics has generated a wide range
of new medical opportunities. Because the relevant
scientific knowledge and organizational skills are
broadly dispersed, no single organization has been
able to internally master and control all the compe-
tencies required to develop a new medicine (Powell
et al. 1996, Pammolli et al. 2000, Orsenigo et al.
2000). Biomedicine, then, is characterized by extensive
reliance on collaboration among many parties, includ-
ing universities, research institutes, new biotechnol-
ogy firms, and mature pharmaceutical and chemical
corporations (Arora and Gambardella 1994, Lerner
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and Merges 1998, Stuart et al. 1999, Arora et al. 2000).
These varied combinations of organizations afford us
the opportunity to analyze cross-national differences
in the roles these diverse organizations play in the
process by which biomedical research moves from
academic laboratories into clinical development.
In §2, we sketch the institutional terrains in Europe
and the United States that have shaped the division
of labor in biomedical innovation. The research sys-
tems in the United States and Europe are organized
in qualitatively different ways, hence any compari-
son must be sensitive to variation on multiple dimen-
sions. We use the methods of correspondence analy-
sis and large-scale network analysis to capture these
systemic differences. Methods and data sources are
discussed in §3. In §4, we present the comparative
analyses, beginning with relational data on collabora-
tive R&D projects. We look at R&D projects that were
originated by public research organizations (PRO),2
and subsequently developed by an array of differ-
ent types of organizations. The distribution shows
U.S.-European variation, as well as numerous cross-
national linkages. To better understand these linkages,
we examine the position of countries in an interna-
tional network of collaborative R&D projects. We then
view these national patterns more closely through an
assessment of patent co-assignment relationships. We
find, again, strong national-level patterns. We ana-
lyze these national-level characteristics by looking at
the focus of R&D at leading research organizations
in Europe and the United States, matching patent-
ing activity with therapeutic categories. These anal-
yses point out the heterogeneity of the U.S. system,
on both scientific and organizational dimensions. We
examine this heterogeneity by mapping the evolution
of interorganizational ties in the United States at the
regional level. We conclude our analyses with a fine-
grained view of the Boston area, one of the leading
centers for biotechnology in the United States.
We assess the implications of our analyses in §5,
stressing the twin importance of integrative capac-
ity (i.e., the ability to move back and forth from
2 We define PRO as any government research laboratory, public
or private university, or nonprofit or public research hospital or
institute.
basic research to clinical development) and relational
capability (i.e., the ability to collaborate with diverse
kinds of organizations). We conclude by noting that
while many analyses of the biomedical systems in
the United States and Europe highlight differences
in financial and labor markets and note key policy
differences (for a review, see Gambardella 2000), we
stress fundamental variation in the organization of the
upstream R&D process.
2. Trajectories of Development in
the United States and Europe
The canonical explanation for differences in the rate
of development of U.S. and European biomedicine
is straightforward, emphasizing first-mover advan-
tage in the growth of small, research-intensive U.S.
biotechnology firms. Along with the biotech boom,
emphasis has been placed on the evolution of
supporting institutions—ranging from federal policy
initiatives (e.g., the 1980 Bayh-Dole Act) to the avail-
ability of venture capital, intellectual property (IP)
law firms, and university technology transfer. We
think this story is accurate, but incomplete. We focus,
in contrast, on the upstream division of innovative
labor. We highlight the importance of the underlying
science and the diversity of organizations involved
in R&D activities. Using data on public-private R&D
relationships, we demonstrate that there are very dif-
ferent constellations of players in R&D networks in
Europe and the United States, and that these partici-
pants are engaged in different kinds of research and
clinical activities. The contrasting stories are signifi-
cant because our argument suggests that while legal
and financial reforms and the availability of venture
capital are necessary, these elements alone may not be
sufficient to generate dense linkages between public
research organizations and industry.
To foreshadow our argument, the United States
is characterized by relationships between U.S. pub-
lic research organizations and firms located in dense
regional clusters that span therapeutic areas, cross
multiple stages of the development process, and
involve diverse collaborators. In contrast, European
innovative networks are characterized by sparser,
more specialized relationships among a more limited
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set of organizational participants located in national
clusters. Both U.S. and European networks are geo-
graphically clustered, then, but in quite different fash-
ions. From these disparate starting points, European
and U.S. innovative networks branch out in divergent
ways.
The science underlying biotechnology was devel-
oped in university and government laboratories.
The leading centers of research in the new molec-
ular biology were dispersed widely throughout
advanced industrial nations.3 Initial technological
breakthroughs—most notably Herbert Boyer and
Stanley Cohen’s discovery of recombinant DNA
methods and George Köhler and Cesar Milstein’s cell
fusion technology to create monoclonal antibodies—
occurred in Californian and British universities. But
from the outset, U.S. universities and academic sci-
entists actively worked to help create the biotechnol-
ogy industry and reap rewards from their involve-
ment (Liebeskind et al. 1996, Zucker et al. 1997,
Mowery et al. 2001). Consequently, small science-
based firms were first located in close proximity
to key universities and research institutes. In time,
established pharmaceutical companies (EPCs) were
also attracted to the field, initially collaborating with
biotech firms in research partnerships and provid-
ing a set of downstream skills that were lacking in
the R&D-intensive startups. Eventually, the consider-
able promise of biotechnology led nearly every EPC
to develop, with varying degrees of success, both
in-house capacity in the new science and a wide
portfolio of alliances with small biotech firms (Arora
and Gambardella 1990, Gambardella 1995, Henderson
et al. 1999).
The early development of dedicated biotech firms
(DBFs) created an initial advantage for the United
States in biotechnology, as close contact between DBFs
and universities became commonplace by the mid-
1980s. Important differences in the nature and level of
support for academic life science research have also
3 A survey of high impact publications in molecular biology
and genetics between 1988 and 1992 lists the Institute Chemie
Biologique in Strasbourg, the MRC lab in Cambridge, UK, the Insti-
tute Pasteur in Paris, and the Karolinska Institute in Stockholm
among the most prolific research centers. See Science Watch,
July/August 1993, Vol. 4, No. 7, Institute for Scientific Information.
played a key role in shaping the comparative advan-
tage of the U.S. system (Gambardella et al. 2000).4
The structure of the research system and the strategies
pursued by funding agencies are crucially important.
In the United States, substantial R&D monies have
been administered through the National Institutes
of Health (NIH), which has supported significant
interaction between the producers of fundamental
biological knowledge and those involved in clinical
research and drug development at public research
centers and universities. Moreover, the U.S. biomed-
ical research system is characterized by numerous
alternative sources of support, with selection mecha-
nisms that complement the NIH and act according to
different principles (Stokes 1997). These varied fund-
ing sources permit diversity to be explored.
In Europe, funding has tended to be adminis-
tered at the national level, with strongly differenti-
ated approaches apparent across countries. European
funding patterns may have hindered the development
of a critical mass, especially in smaller countries. In
many cases, resources have either been spread among
a large number of “small” laboratories, or they have
been excessively concentrated in the one or two cen-
ters of excellence. Support coming from the various
European-wide programs has only partially changed
the situation. In addition, research funds are much
less likely to support integration between basic sci-
ence and clinical development.
European biomedical research has also been con-
siderably less integrated with teaching. The relevance
of the research-teaching nexus in fostering high-
quality scientific research and integrating academic
and industrial science should not be understated. In
particular, the diffusion of molecular biology into gen-
eral training in many European countries is a rela-
tively recent phenomenon. As compared to the United
States, molecular biology research has tended to be
confined to highly specialized university and research
institute laboratories (Morange 1998). Particularly
in Continental Europe, policies have been targeted
mainly to creating specific organizational devices to
4 Pavitt (2000) estimates that the resources devoted to academic
research in the life sciences in the United States are 50% larger than
in Europe.
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manage technology transfer, such as science and tech-
nology parks. These intermediary institutions may
even increase the distance between universities and
industry by introducing an additional layer to the
relationship. We argue that these institutional dif-
ferences in funding, and the relationships among
research, clinical work, and teaching, shape the struc-
ture of university-industry R&D networks in the
United States and Europe.
Partly as a consequence of the institutional differ-
ences sketched above, the founding of new biotech-
nology companies in Europe was more difficult. Rates
of formation of start-ups are strongly correlated with
the strength of university and public research insti-
tutes in the underlying science (Zucker et al. 1997). In
the absence of small local firms, the large European
companies turned to small American partners to tap
new competencies as they struggled to catch up.
Given the head start and faster rates of techno-
logical development in the United States, European
start-ups may have been pre-empted by American
firms. Moreover, the more dominant large European
pharmaceutical firms have had a pronounced effect
on the development of European R&D networks, as
these organizations serve a “clearing-house” function
for the development of more specialized innovations
from national research clusters.
3. Data and Methods
Analyzing cross-national differences in research fund-
ing, organization, and practice, as well as differential
integration across R&D, clinical activity, and teach-
ing is most effectively accomplished with methods
that visually represent these patterns of relationships.
We are less interested in the attributes of individ-
ual research organizations and much more concerned
with the linkages that structure innovation systems.
Hence we utilize methods that capture these relational
features graphically. We use correspondence analy-
sis and graph-drawing techniques to examine key
characteristics of life science knowledge networks.
Correspondence analysis is an analytical technique
for studying the canonical correlations between two
(or more) sets of categorical variables.5 We perform
5 For illustration, see Greenacre (1984, 1993).
correspondence analyses to visually represent corre-
lations among therapeutic patent classifications and
public research organization assignees in a common
two-dimensional space.
We adopt a general analytical technique based on
the theory of random fields (Ising 1925, Guyon 1994)
to graphically display collaborative networks at the
national, cross-national, and organizational level.6
Specifically, we applied the Fruchterman-Reingold
(FR) algorithm (1991) to simulate our network of
collaborations as a system of interacting particles
with repelling forces uvx = c21/dxuxv between
every pair of nodes uv ∈ V , and additional attract-
ing forces uvx = dxuxv2/c1, which are in place
only between connected nodes, where dxuxv is the
Euclidean distance of locations xu and xv of nodes u
and v, respectively. The parameter c1 is set to c2
√
A/n,
where A is the desired layout area, n is the number
of nodes, and c2 is an experimentally chosen constant.
The FR algorithm aims to minimize the force on each
node, which is equivalent to minimizing the energy,
U , of the overall random field:
Uuvx=


auvx−SLvarrhouvx if nodes u and v are
connected
SLvarrhouvx otherwise
More precisely, the FR algorithm is designed to find
a stable configuration corresponding to a local mini-
mum. To prevent the algorithm from resting in sub-
optimal local outcomes and to improve the fit of the
final configuration, we run the algorithm with several
randomly chosen initial layouts. At the end, the draw-
ings we present to illustrate our argument capture not
only the pattern and density of collaborative activ-
ity, but also are a meaningful indicator of the extent
to which such collaborations create actual clusters of
tightly connected partners.
6 The theory of random fields provides a unified theoretical frame-
work to cope with large systems of interacting agents in the nat-
ural and social sciences. The reader interested in the relation-
ship between the theory of random field and graph-drawing tech-
niques is referred to Brandes and Wagner (1997), Guyon (1994), and
Winkler (1995). A software package for large network analysis is
available online at http://vlado.fmf.uni-lj.si/pub/networks/pajek.
Pajek has been used to analyze multiple types of large networks
(Batagelj and Mrvar 2000, Albert et al. 2000).
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We draw on several complementary data sets to
analyze European and U.S. research organization-
industry innovation networks for the period spanning
1988–1999. Two patent data sets and two research
collaboration data sets form the core of our analy-
ses. The databases, referred to in the tables and fig-
ures as “U.S. Biomedicine,” developed by Powell and
Kenneth Koput and by Owen-Smith, focus primar-
ily on the United States. In their examination of the
role research universities play in the commercial field
of the life sciences, they find 1,026 linkages between
public research organizations and dedicated biotech
firms over the 12-year period. For each relationship,
data are available on the purpose of the affiliation, its
duration, and the identities of the participants. These
relationships represent formal contractual ties estab-
lished between firms or through the auspices of the
United States Patent and Trademark Office. The larger
database from which these relationships are extracted
focuses on dedicated biotechnology firms (Powell and
Koput) and Research One (R1) universities as desig-
nated by the Carnegie Foundation classification sys-
tem (Owen-Smith 2000). Both databases have been
used extensively in previous research (Powell et al.
1996, Powell et al. 1999, Owen-Smith 2000, 2001).7
The biotech database covers independently oper-
ated, profit-seeking entities involved in human thera-
peutic and diagnostic applications of biotechnology.8
The sample includes 482 firms, 180 of which exist in
all years over the period 1988–1999. There were 229
entrants during the period, and 91 exits overall. The
7 For detail on the Powell-Koput database, see Powell et al. (1996,
pp. 124–129) and Powell et al. (1999, pp. 136–140). For detail on
the Owen-Smith database, see Owen-Smith (2000, pp. 59–66 and
76–81).
8 These data focus on dedicated human biotechnology firms. Com-
panies involved in veterinary and agricultural biotech, which draw
on different scientific capabilities and operate in a much differ-
ent regulatory climate, are omitted. We also exclude companies
that are wholly owned subsidiaries of pharmaceutical and chemi-
cal corporations. We do, however, include biotech companies that
have minority or majority investments in them by other firms, so
long as the company is independently traded on the stock mar-
ket. Our rationale for excluding both biotech subsidiaries and large
diversified corporations is that the former do not make decisions
autonomously and biotechnology may represent only a small por-
tion of the latter’s activities.
database, like the industry, is largely centered in the
United States, although in recent years there has been
significant expansion in Europe. In 1999, 80% of the
companies were located in the United States, whereas
10% made their homes in Europe. The U.S. university
database focuses on the role that research-intensive
campuses have played in biotechnology through the
specific lens of patent co-assignment. Using a data
set coded from bibliographic information drawn from
patents assigned to 89 R1 universities from 1976–1998,
we identified 181 co-assigned pharmaceutical patents
that were jointly owned by R1 universities and ded-
icated biotech firms or non-university research insti-
tutes and hospitals.9
Pammolli and Riccaboni have developed two com-
prehensive data sets with extensive coverage of
Europe and the United States. The Pharmaceutical
Industry Database (referred to as PHID) developed
at the University of Siena covers 4,358 collaborative
R&D projects among industrial and nonindustrial
sources.10 For each R&D project, the PHID database
distinguishes the organization that originated a new
pharmacologically active compound from the orga-
nization(s) that licensed that patent for further
development. In addition to this originator-developer
distinction, each project is classified according to
the Anatomic Therapeutic Classification (ATC), which
identifies pharmacological actions and biological
targets.11
9 To accomplish this we use a recent Office of Technology Assess-
ment and Forecasting crosswalk between United States Patent
Office subject area classifications and three-digit Standard Indus-
trial Classification product codes. Patent co-assignment represents
shared ownership of intellectual property and, as such, indicates a
particularly close and potentially consequential form of interorga-
nizational collaboration. Co-assignment limits each partner’s ability
to unilaterally appropriate rents from intellectual property. Thus, it
is not a relationship that organizations (especially for-profit organi-
zations) enter into lightly. Co-assignment is common in cases where
patents have multiple inventors who are employed by different
organizations.
10 For further details about the PHID, see Riccaboni (2000, pp. 9–11
and 31–33).
11 The ATC classification has been developed and maintained since
1971 by the European Pharmaceutical Marketing Research Associa-
tion. The three-digit ATC designation is a widely accepted standard
for classifying pharmaceutical products and is used by anti-trust
associations around the globe.
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The second database, referred to in the tables as
“Patents,” draws on 8,031 patents for therapeutically
useful compounds or processes issued by major world
patent offices (United States, United Kingdom, Ger-
many, France, Japan, European, and the Patent Coop-
eration Treaty legal office) and assigned to the 98 most
prolific nonindustrial research organizations world-
wide.12 These 98 institutions represent more than 70%
of all nonindustrial patents in this sample. Thus, there
is a natural cutoff point at 98, as the remainder of
the distribution is very widely dispersed across hun-
dreds of organizations. These patents were also coded
according to the same pharmacological classification
used for R&D projects.
Taken together, these four data sources permit us
to develop a comprehensive and novel view of patent
co-assignment and collaborative networks involving
European and U.S. biotechnology firms, pharmaceu-
tical corporations, and public research organizations.
Our data are broad in scope and involve thousands of
relationships among multiple types of organizations,
enabling us to map qualitative differences in public-
private R&D networks in the life sciences.
4. Analyses: Cross-National
Networks and Organizational
Competencies in R&D
We begin by presenting data on R&D projects gen-
erated by PROs and developed collaboratively with
12 Information on the patents is found in Patent Fast Alert, published
by Current Drugs, Ltd., London, U.K.
Table 1 Developers for Public Research Organization–Originated R&D Projects
Type of Developer
EPC DBF PRO n by pair type
Euro PRO –> Euro Partnertotal 239% 429% 332% 669
Euro PRO –> Euro Partnerw/in country 139% 466% 395% 476
Euro PRO –> Euro Partneracross country 487% 337% 176% 193
Euro PRO –> U.S. Partner 226% 494% 280% 243
U.S PRO –> Euro Partner 662% 259% 71% 719
U.S PRO –> U.S. Partner 176% 544% 280% 2727
n by developer 1,170 2,078 1,110 4358
Source. PHID.
other organizations.13 We distinguish the roles of
originators and developers, with the former respon-
sible for the underlying basic science, focusing on
the early stages of target identification/validation
and drug discovery, and the latter handling down-
stream stages of R&D and subsequent manufacture
and/or marketing. We identify originators as the
institution that started the R&D project and, typi-
cally, held the relevant patent. Note that a variety of
organizations—PROs, DBFs, and EPCs—perform the
roles of developing, producing, and commercializing
new biomedical products.
As Table 1 indicates, the bulk of the collaborative
projects occurs within the United States, while a much
smaller number are carried out in Europe. We are
somewhat less interested in the scale of activity than
in what kind of organizations are involved. In the
United States, dedicated biotech firms do the lion’s
share of the development work (nearly 55%) on PRO-
originated innovations. When a U.S. PRO turns to a
European partner, the large multinational corporation
is the dominant option. In Europe, there are real dif-
ferences in collaboration within and across nations. In
local within-country collaborations, European PROs
turn to DBFs and other PROs. But when collabora-
tion occurs across European countries, the EPCs again
become the dominant partner. When European PROs
reach across the Atlantic, U.S. DBFs are the primary
developers. The picture that emerges is one of very
13 In this article we focus only on the PROs as originators, and
do not examine cases where DBFs and EPCs are sources of new
research opportunities or cases where PROs were developers for
PRO originators.
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different roles for small firms and large multination-
als in Europe and the U.S. The large pharmaceuticals
are responsible for the bulk of cross-national collabo-
rations in Europe, while the small biotechs are the key
developers in the U.S. We turn now to an in-depth
examination of these organizational differences.
Organizational Underpinnings
Figure 1 represents the R&D projects data graphically,
locating the position of nations in a global network.
In this figure the spatial position of the nodes rep-
resents the relative centrality of individual nations
in the international R&D project network. The size
of the nodes corresponds to the number of biomed-
ical patents held by PROs in each nation. Thus,
node size reflects relative differences in the stock of
patented biomedical knowledge held by PROs in each
nation, and indicates the volume of innovations gen-
erated by each national research system. The numbers
Figure 1 Cross-National Network of R&D Projects Involving PROs and Commercial Entities, 1990–1999
Source. PHID, Patents.
associated with the lines are counts of the num-
ber of cross-national R&D agreements. For exam-
ple, the close connection between the United States
and the United Kingdom represents 441 individual
R&D project ties between PROs and commercial enti-
ties. Figure 1 portrays several key characteristics of
the international biomedical R&D projects network,
reflecting relative national positions in terms of both
stocks and international flows of knowledge.
Note the centrality and size of the American node.
The large and diverse public research system in the
United States dominates global patenting and is cen-
tral in the cross-national project network. This cen-
trality is reflected in the spatial location of the node
(a result of Pajek’s clustering algorithm), in multiple
connections to otherwise isolated European nations
(e.g., the Netherlands, Spain, Belgium, and Denmark),
and in high volume cross-national ties. Note that each
international link involving the United States rep-
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resents a higher volume of individual R&D agree-
ments than any of the cross-national ties between
other nations. Figure 1 clearly implies that the public
research organizations in the United States are struc-
turally central and quantitatively dominant in cross-
national R&D project networks.
The nationally aggregated picture presented in
Figure 1 does not tell the full story, however. R&D
projects and patented biomedical innovations stem
from the work of scientists and clinicians in organi-
zations. Figure 2 examines the upstream collaborative
network among individual PROs to analyze relation-
ships among organizations whose patenting activity
drives the size of the nodes in Figure 1. Figure 2 is
based on patent co-assignment networks among pub-
lic research organizations. Each node is a university,
research institute, or hospital, and each tie represents
two or more patent co-assignments between the orga-
nizations. As was the case with Figure 1, the rela-
tive spatial position of nodes is a reflection of the
minimum-energy algorithm we employ using Pajek.
Several features stand out in this image.
Consider first the regional and national clustering
of organizations that we highlight with dashed and
dotted lines. The tightly clustered French, German,
and British research organizations on the left side of
the figure and the densely connected U.S. regions in
the image’s upper right-hand quadrant are the result
of minimum-energy network drawing techniques and
not of arbitrary placement. In addition to demon-
strating the coherence of national and regional R&D
systems, the patterns of patent co-assignment help
explain the causes of the U.S. dominance apparent
in Figure 1. Note the organizational homogeneity of
the French and German national clusters, which do
not include hospitals and have no identified univer-
sities.14 The United Kingdom has a somewhat higher
degree of organizational diversity, reflected by the
presence of both government and nonprofit research
and funding agencies. Contrast these relatively iso-
lated and homogeneous national clusters with the
large and densely interconnected Boston region in the
14 Scientists at the CNRS or Max Plancks may well have univer-
sity laboratories, but the government institute is identified as their
primary affiliation on the patents.
upper quadrant of the figure. Boston is composed of
tight, repeated interconnections among a diverse set
of PROs. Elite universities (Harvard, MIT), research
institutes (the Dana-Farber Cancer Center), and hospi-
tals (Brigham and Women’s and Massachusetts Gen-
eral) play central roles in innovative collaborations
both within Boston and across U.S. regions.
Closely knit regional networks such as those
found in Boston help account for the global cen-
trality of American PROs. But connections across
U.S. regions (note, for instance, the ties between
Harvard, Stanford, and the UC system, connections
from Dana-Farber to the University of Chicago, and
from Brigham and Women’s Hospital to Duke Uni-
versity) and co-assignment ties linking geographi-
cally dispersed universities to the National Institutes
of Health illustrate a public research system that
also reaches across regions and organizational forms.
Recall that these relationships represent patent co-
assignments, a particularly close form of R&D collab-
oration. We argue that these systemic cross-national
variations in the organization of early-stage research
collaborations explain national differences in biomed-
ical commercialization above and beyond variations
in policies or later-stage technology transfer infra-
structures. Consequently, we expect the structural
clustering of European nations and U.S. regions, and
the consolidating effect of inter-regional ties in the
U.S., to result from characteristics of the science
underlying these patent co-assignment networks. To
consider this assertion, we turn to correspondence
analyses of the specific therapeutic areas covered by
public research institute patents in the United States
and Europe. As we use the term here, a therapeutic
class is one of 102 specific disease areas on which a
patented innovation focuses. Thus we can distinguish
both the scientific content and the specific target of
patented research in the United States and Europe.
The Organizational Division of Scientific Labor
Figures 3 and 4 display the outputs from cor-
respondence analyses relating U.S. and European
public research organizations and the therapeutic
classes in which they patent. Correspondence analy-
sis is applied here to capture substantial differences
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Figure 2 Organizational Level Patent Co-assignment Network for PROs, 1990–1999
Source. PHID, Patents.
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Figure 3 Correspondence Analysis: Co-location of Prolific European Patentors and Therapeutic Classes, 1990–1999
Source. Patents.
∗The percentages represent the proportion of interinstitutional variance in technological profile accounted for by the x and y axes.
between leading U.S. and European research insti-
tutions in terms of scientific specialization.15 As an
output, correspondence analysis provides a graphical
representation in a chi-squared metric such that insti-
tutions with profiles close to the average are plotted
near the origin, while more specialized profiles are
plotted on the periphery. In Figures 3 and 4, the bold-
faced labels represent the most prolific PROs in terms
15 Correspondence analysis allows us to deal simultaneously with
organizational and scientific profiles of the U.S. and European pub-
lic research systems. For readers not familiar with dual scaling tech-
niques, it may be worthwhile to notice that correspondence analysis
is essentially a variant of principle component analysis tailored to
categorical rather than continuous data (Hill 1974, Greenacre and
Hastie 1987, p. 437). As with principle component analysis, cor-
respondence analysis does not provide cut-and-dried conclusions,
instead it is an explanatory technique that offers a framework for
interpretation (Greenacre 1993, p. 85).
of number of patents, while the lighter labels denote
therapeutic macro-classes. Institutions and therapeu-
tic categories play dual roles, weighting organiza-
tional profiles and rescaling the dimensions of the
figures. Here again, the spatial relationships among
PROs and therapeutic classes are meaningful rep-
resentations of quantitative relationships. Interpoint
distances are reflective of differences in institutional
therapeutic profiles. For example, if a given institution
holds the same number of patents for each therapeutic
category, then it will be centrally located. In contrast,
an institution specialized in one class will appear on
the periphery of the correspondence map.16
16 To allow the same interpretation for therapeutic classes in the
space defined by research organizations, we rescaled organiza-
tion scores as suggested in Carroll et al. (1986). As a result,
the plots in Figures 3 and 4 that report both institutions and
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Figure 4 Correspondence Analysis: Co-location of Prolific U.S. Patentors and Therapeutic Classes, 1990–1999
Source. Patents.
∗The percentages represent the proportion of interinstitutional variance in technological profile accounted for by the x and y axes.
Figures 3 and 4 demonstrate that while research
is proceeding on substantively similar topics across
the continents, the division of organizational labor
that produces it varies greatly. Note the big dif-
ferences in the types of core actors. In the Euro-
pean case (Figure 3) universities are underrepre-
sented. Instead, research institutes such as France’s
Institute Pasteur and Germany’s Max Planck and
Max Delbruck centers play important roles. This cen-
trality is not surprising, given the preeminent role
of these institutes in the history of molecular biol-
ogy (Morange 1998). In contrast, Figure 4 reprises
Figure 2, showing that the core actors in the U.S.
innovation system are much more organizationally
therapeutic categories in rescaled standard coordinates are symmetric
(Greenacre 1993).
diverse. Note the centrality of the U.S. government
(the National Institutes of Health complex), Johns
Hopkins University, and the University of California
System. But also observe the key presence of elite
research institutes such as Scripps and Salk, major
research hospitals and medical schools (Brigham and
Women’s, Massachusetts General, and Baylor College
of Medicine), as well as other top research universities
(MIT, Stanford, Pennsylvania, Duke, and Rockefeller).
The clear implication is that the universe of central
public research organizations is much more heteroge-
neous in the United States than in Europe.
Observe the relative dispersion of therapeutic
classes that appears in both Figures 3 and 4. For
Europe, Figure 3 indicates a fairly dispersed set
of therapeutic classes, suggesting that the organiza-
tions associated with them are specialized innovators
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whose patents focus on specific sets of therapies and
biological targets. In contrast, therapeutic classes are
not clearly separable in Figure 4, indicating that lead-
ing U.S. PROs hold patents that span multiple sub-
stantive areas. Finally, consider the co-location of ther-
apeutic classes and public research organizations in
the two figures. Figure 3 highlights not only spe-
cialization by organizational form, but also national
specialization in areas of innovation. There are two
apparent clusters of research institutes and thera-
peutic classes. The French institutes on the left-hand
side of Figure 3 are located close to each other and
co-located on a distinctive set of therapeutic classes
relating primarily to infectious disease and AIDS
research. German research institutes, at the right-hand
side of the figure, are more involved with hered-
itary cardiovascular diseases. The more dispersed
and diverse British institutions, e.g., Cancer Research
Campaign (CRC), Medical Research Council (MRC),
and the British Technology Group (BT), are some-
what broader in focus but still cluster in therapeutic
classes largely related to cancer research. The greater
breadth of the British research system, and its higher
degree of diversity compared to France and Germany,
may explain its more central role in international
R&D networks (recall Figure 1). Figure 4, on the other
hand, tells a quite different story. In the U.S. national
innovation system, diverse public research institu-
tions play the role of generalist innovators regard-
less of geographic location, though the prevalence
of Boston- and California-based research organiza-
tions in the core suggests the importance of regional
agglomeration.
These differences in the organization of science
are critical, suggesting that increases in scale alone
will not alter the focus of R&D efforts. Organiza-
tions typically engage in local search, and thus con-
tinue to patent in those areas in which they are most
skilled. In essence, then, we argue that one reason
for greater integration across and within U.S. regions
can be found in the scientific overlap among gener-
alist patentors. Alterations in the scale of patenting
activity without corresponding shifts in this division
of labor will not make the European system resem-
ble its American counterpart. Instead, we contend
that mere increases in scale might deepen special-
ization and heighten fragmentation among European
national research systems.
One key message of the correspondence analyses is
that national specialization in Europe falls along sci-
entific lines. In the United States, there is abundant
regional clustering, but, unlike the European case,
agglomeration is not driven by scientific specializa-
tion. Points of excellence develop in both the United
States and European systems, but in Europe those
clusters are limited to narrower medical specialties
and specific nations. The U.S. has a very different pro-
file, characterized by diverse, substantively general-
ist research organizations connected both within and
across key regional clusters. To further understand-
ing of the organization of the U.S. national system,
we turn to an analysis of its growth out of a few key
regional clusters.
A National System from Regional Origins
We have stressed the dual role of universities and
start-up firms in biotechnology’s origins. Here, we
present data that confirm the co-location of uni-
versities, research institutes, and dedicated biotech
firms in a small number of geographic regions in
the United States. In 1988, 73% of all collaborations
between DBFs and PROs occurred in just six areas:
Boston, the New York metropolitan area, Seattle, San
Diego County, the Bay Area, and Texas (principally
Houston).17 This phenomenon has been attributed to
a range of intellectual, economic, and social factors.
Knowledge spillovers are clearly important, especially
when novel discoveries are involved. The availabil-
ity of skilled labor and access to venture capital
17 Those six regions contain 14.6% (13) of the universities, 14.3% (24)
of the research institutes and hospitals, and 27.2% (131) of the DBFs
in our sample. Clearly the aggregate concentration of ties in clusters
is a function of their concentration in a handful of organizations.
We do not attempt to separate the effects of organizational and geo-
graphic concentration of ties here. Instead, we content ourselves
with noting their importance for a full understanding of regional
and industry development. We treat each of the clusters as coherent
units for the purposes of cross-national comparison, but we recog-
nize that each area is itself a complex system of relationships with
a core and periphery and a distinctive evolutionary trajectory. The
same factors that we expect to affect industry development at the
national level also play out within regions.
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are critical as well. Extensive social ties and reputa-
tional credibility catalyze further relationships, sus-
taining a process of increasing returns. But how do
initial locational advantages and rapid technological
development interact? In addition to institutional and
labor market differences, we argue that the structure
of scientific knowledge in biomedicine plays a key
role.
The field of the life sciences has witnessed a rapid
expansion of knowledge that has taken the form of
a branching process, in which general hypotheses
have given rise to subhypotheses, and in turn to fur-
ther inquiries (Orsenigo et al. 2001). The structure
of knowledge is hierarchical, highly cumulative, and,
in the industry’s early years, difficult to appropri-
ate without close contact with cutting edge academic
researchers. But discoveries that were considered rev-
olutionary at the outset were soon incorporated into
the standard toolkit of laboratory practice. As the
skills became widely accessible and new transversal
technologies (e.g., genomics, combinatorial chemistry,
and high throughput screening) allowed for sophis-
ticated production and screening of new molecular
structures absent contact with established research
centers, DBF dependence on prestigious university
researchers declined, and the central importance of
network connections to local partners waned.
We seek to explain how the evolution of the sci-
ence has affected the network of collaborative rela-
tionships. Several possibilities can be sketched, with
different roles for various types of institutions. For
example, universities and firms that were first movers
on the research frontier could continue their close ties
as the research moved into clinical development. But
as initial successes are achieved and publicized, many
other participants are attracted to the field, both in
the United States and abroad. An alternative process
could involve the initial entrants as the carriers of
the field, moving from co-localized relationships to
more distant linkages with other firms and univer-
sities. This process might be driven by a production
logic, in which diffusion occurs with movement from
upstream R&D to downstream commercialization. A
different trajectory would emphasize the catalyzing
role of geographic centers, stressing the capacity of
initial entrants to identify new knowledge and rele-
vant skills developed outside their regions. In this sce-
nario, the most well-connected early entrants would
be the most capable at accessing new ideas (Koput
and Powell 2001). Combined with the overwhelming
initial importance of regional clusters, this latter pat-
tern implies that we should observe a process of delo-
calization of PRO-DBF ties over time. This delocal-
ization would be facilitated by the generalist research
focus of core organizations highlighted in Figure 4.
We begin by mapping alterations in the level
of geographic clustering of PRO-DBF relationships
in the United States. The biotechnology industry’s
early development in the United States depended
on regional concentrations of co-located universi-
ties, firms, research organizations, and key resource
providers such as law and venture capital. Thus the
earliest linkages between biotech firms and public
research organizations should be dominated by rela-
tionships in which both partners are co-located in
the same geographic region. If this sector evolves as
established “local” players expand their set of poten-
tial partners and as new technologies become stan-
dard practice, then the proportion of ties with region-
ally co-located or “local” partners should decline over
time.
Figure 5 presents both graphical and quantitative
evidence for the process of industry evolution. The
figure on the left represents 1988, on the right, 1998.
The triangles represent the six most active regions
where biotechnology originated, and their location on
the pyramid reflects the volume of the interorgani-
zational linkages that connect them to other areas.
The size of the triangle reflects the number of ties
within the region. Thus, Boston is both the most
connected region internally and the most extensively
linked externally.
Note the aggregate decline in the percentage of
local ties from a high of just over 40% in 1988 to a
low of 8% in 1998. This decline occurs in the context
of a rising volume of collaborations, the number of
ties active in 1998 is more than double the number a
decade before. The combination of an increasing num-
ber of collaborations and a decreasing proportion of
local connections represents the declining importance
of ties within the initial regional clusters. Figure 5
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Figure 5 (A) Interorganizational Linkages by Region in the United States, 1988 (B) Interorganizational Linkages by Region in the United States, 1998
Source. U.S. Biomedicine.
indicates that the growing volume of PRO-industry
ties in U.S. biomedicine occurred in the context of
a shift in the distribution of those ties, such that
the importance of geographic propinquity decreased,
while the prevalence of network linkages between
organizations in different areas increased.
As noted above, the sharp decline in local ties
within established regions could, in the context of
an aggregate increase in connections, result from
three very different trajectories: (1) deepening ties
across established regions (e.g., links between trian-
gles in Figure 5); (2) connections from established
regions to other areas of the nation (e.g., ties con-
necting nodes above the dashed lines to those below
it); or (3) increasing linkages involving two part-
ners located outside established regions. Figure 5
shows that the second of these options describes the
bulk of changes in the regional distribution of ties
as the U.S. national network expanded over a 10-
year period. While within-cluster and cross-cluster
ties declined, and ties that do not involve established
clusters showed only a slight increase, the proportion
of linkages involving a partner in an established clus-
ter and one in another region of the country more
than doubled, accounting for about 54% of all connec-
tions by 1998.
We contend that this important structural shift illu-
minates a dual process of network expansion that
encompasses both increased scale and a shifting geo-
graphic distribution. In our view, this transforma-
tion is enabled by both the generalist scientific role
played by elite PROs within established regional clus-
ters (recall Figure 4) and by the integrative role of
the National Institutes of Health (recall Figure 2).
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Moreover, the regional clusters that gave birth to the
U.S. national network may have already contained the
seeds of this change.
We turn to closer analysis of one U.S. regional
“starting point” to examine this possibility. A per-
sistent question we have entertained is whether the
U.S. system is simply different and more diverse
because of its larger scale. So we examine a single
regional cluster at an early point in its development to
ascertain whether organizational diversity and inte-
gration between research and the clinic were present
from the founding of the field. Consider Figure 6,
which presents two views of interorganizational link-
ages involving the Boston region, the most prominent
regional cluster apparent in Figures 2 and 5. Figure
6A represents only linkages internal to Boston in 1988.
These are the specific interorganizational ties repre-
sented by the size of the Boston node in Figure 5.
Figure 6B highlights all ties involving at least one
partner in the Boston area in the same year. In both
Figure 6 (A) DBF Ties Internal to the Boston Region, 1988 (B) PRO–DBF Ties Internal and External to the Boston Region, 1988
Source. U.S. Biomedicine.
cases, the shape of nodes represents the type of orga-
nization. Triangles are universities, circles are DBFs,
and squares are research institutes or hospitals. Node
size is a function of network degree such that the
largest nodes are the most connected. As with other
Pajek representations, the location of nodes relative to
each other is a function of the strength and pattern
of ties among them. Figure 6B adds shading to the
image to capture the geographic location of partners.
Black nodes (of any shape) are located in the Boston
metro area. Gray nodes are located in one of the other
established regional clusters (Figure 5’s triangles), and
white nodes are located in other areas of the country.
In Figure 6A, the organizational diversity of the
Boston area in 1988 is clear. Firms (e.g., Seragen,
Genzyme, Cambridge Bio), universities (Tufts, Har-
vard, MIT, BU), research institutes (Dana-Farber), and
hospitals (Brigham and Women’s, Massachusetts Gen-
eral) are connected to local partners. Nevertheless,
that organizational diversity is apparent in a rela-
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tively sparse network of connections that makes the
Boston region look less clustered than our earlier anal-
yses suggest. A key research institute and a hospital
(Brigham and Women’s and Dana-Farber) are isolated
from the central network corridor. Viewed through
a Boston-only lens, the region appears composed of
loosely connected clusters surrounding MIT and Har-
vard. Organizational heterogeneity was common in
Boston in 1988, but the early density of the Boston net-
work appears to be a function of organizations located
in other areas of the nation.
At a glance, Figure 6B looks more like a coher-
ent regional network than Figure 6A. Three impor-
tant clusters (surrounding Dana-Farber, Harvard, and
MIT) are brought into closer connection by diverse
organizations located outside of Boston. Consider the
structural roles played by the UC system, Stanford,
Centocor (a Philadelphia-based DBF), and the Sloan-
Kettering Cancer Institute (located in New York City).
These four organizations add a coda to our story
of organizational diversity. While Boston is inter-
nally diverse, the density of the region’s innova-
tion networks is greatly increased by the inclusion
of diverse organizations from other geographic loca-
tions. Figure 6B captures a single regional “starting
point” and demonstrates that the diversity and den-
sity of Boston’s networks is a function of both local
depth and ties that connect multiple regions. Note
also the key role played by Boston DBFs in reach-
ing out to PROs located in other areas of the country.
Recall from Figure 5 that it is exactly this type of tie
(indicated by connections from black nodes to white
nodes in Fig. 6B) that promotes the expansion of the
U.S. national system. Unpacking the structure of the
PRO-DBF network in Boston at an early time provides
two key insights into the development of the U.S.
national systems documented in Figure 5. First, the
seeds of that expansion were already present in one
focal region as early as 1988. The lesson of Figure 6B
is that ties to key organizations in other parts of the
country helped make Boston a major regional starting
point. Second, Figure 6B emphasizes the central role
that small science-based firms played in connecting
with other areas of the nation. A quick glance at the
local Boston nodes (black) in the figure suggests that
it is DBFs such as T Cell Sciences that connect to geo-
graphically distant PROs rather than the elite PROs
linking to distant firms.
In essence, the dual process we highlight reveals
that a national U.S. biomedical network grew from
regionally clustered beginnings on the strength of
overlapping scientific expertise, the critical integra-
tive effect of the NIH, and the expansive role played
by small firms. In the European case, the absence
of strong scientific overlap (recall the national sci-
entific specialization apparent in Figure 3), a sin-
gle key upstream institution such as the NIH, or
rapidly developing small firms mitigate against this
type of network expansion. These critical differences,
we argue, have several notable consequences. First
the relative homogeneity of elite European PROs—
few European universities and no European hospitals
appear in either Figure 2 or Figure 3—suggests that
in addition to scientific specialization, European net-
works will be less integrated across the development
process than their U.S. counterparts, which include
universities, hospitals, and research institutes. Second,
the integrative role played by the U.S. National Insti-
tutes of Health occurs much further downstream in
Europe, as large pharmaceutical companies undertake
the bulk of cross-national European research collab-
orations (recall Table 1). Finally, there is a very dif-
ferent role for small science-based firms in the U.S.
and European contexts. Where Figure 6 shows that as
early as 1988 it was small firms in Boston that were
linked to disparate and geographically diffuse PROs,
Table 1 indicates that in Europe, small firms play
a local role, deepening ties within scientifically spe-
cialized national clusters rather than reaching across
them.
5. Conclusions
Our analyses of university-industry interfaces in the
United States and Europe emphasize the importance
of the division of innovative labor. We do not object to
arguments that the United States’ first-mover advan-
tage was critical in establishing the trajectory of the
field. But we supplement this explanation by stress-
ing the diversity of actors involved and the varied
roles played by scientific specialists and generalists.
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Without recognizing these elements in the context
of an evolutionary trajectory shaped by distinct cul-
tural and institutional contexts, European efforts to
“catch up” to the United States by mirroring estab-
lished policies and arrangements will likely be mis-
guided. Central to the U.S. system are two key factors:
relational and integrative capability. A wide diver-
sity of U.S. organizations has established protocols in
place for fostering research collaboration. Moreover,
these alliances span organizations with different mis-
sions and serve to link basic research with clinical
development.
The institutional structure of biomedical research
evolved quite differently in Europe and the
United States. The diversity of the U.S. public research
system, a highly mobile scientific labor force, and a
host of regulatory and policy initiatives promoted
widespread commercialization of academically origi-
nated research, largely through the founding of small
biotechnology firms. In addition, the generalist tech-
nological role and integrative development profiles
of U.S. public research organizations have capitalized
on scientific developments in molecular biology that
more closely link goal-oriented therapeutic research
with fundamental biological investigation. European
universities developed competencies in molecu-
lar biology less quickly than specialized research
institutes. The disciplinary focus of these institutes,
combined with the centralizing effects of national
R&D funding infrastructures and regulatory contexts,
serve to limit universities’ participation in commer-
cially oriented R&D and concentrate R&D networks
in specialized national clusters.
We also observe qualitively different paths in the
development of local centers of excellence in the
United States and Europe. In the former case, general-
ist regional clusters developed around public research
organizations that integrated innovation and devel-
opment work. These clusters planted the seeds of
accumulative advantage as the regions attracted tal-
ented researchers, high quality students, and increas-
ing shares of R&D funding, in addition to for-profit
firms dedicated to the commercialization of new tech-
nologies. In Europe, national clusters of specialists
may also have benefitted from accumulative advan-
tage in research funding and talent, but the fund-
ing sources were national rather than European, and
research priorities and a community of local special-
ist firms may have deepened already narrow com-
petencies rather than enabling broad exploration.
The role that European pharmaceutical corporations
played as clearinghouses for innovations developed
within these national clusters may have also mitigated
against the broadening of regional scientific and orga-
nizational competencies.
Finally, notable differences in the constellation of
organizations able to capture and develop innova-
tions aided in pushing U.S. and European indus-
tries in different evolutionary directions. We observe
divergent roles played by public research organi-
zation originators, dedicated biotechnology firms,
and large pharmaceutical companies that contribute
to disparate industry outcomes in Europe and the
United States. Our emphasis on the diversity of types
of organizations and their multiple roles stands as a
corrective to policy attempts to develop high volume
collaborations in Europe through copying American
policies. Our focus on the division of innovative labor
implies that European efforts to adopt U.S. policies
should be directed more at generating integration
between basic research and clinical development and
fostering extensive linkages among universities, small
firms, and the heretofore dominant public institutes
and large pharmaceutical companies.
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